Literature DB >> 12354895

Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.

Erja Chryssanthou1, Manuel Cuenca-Estrella.   

Abstract

The proposed standard of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST) and the E-test procedures were compared with the NCCLS reference broth microdilution method for voriconazole and caspofungin susceptibility testing of 102 clinical Candida species and Saccharomyces cerevisiae isolates. The voriconazole MIC at which 50% of strains were inhibited (MIC(50)) was < or =0.125 mg/liter for all yeast species except for Candida glabrata and Candida krusei, which yielded MIC(50) values of 0.25 to 1 mg/liter depending on the method. Caspofungin exhibited in vitro activity (MIC(50) of < or =0.125 to 2 mg/liter) against all yeast species except for Candida guilliermondii. The agreements between MICs within +/-2 dilutions obtained by the NCCLS method and the EUCAST standard were 97% for voriconazole and 96% for caspofungin. Intraclass correlation coefficients were statistically significant (P < 0.05). The agreements between voriconazole MICs provided by the E-test and the NCCLS and between the E-test and the AFST-EUCAST method were 100 and 90%, respectively. Because of lower caspofungin MICs provided by the E-test, the agreement was slightly poorer with the NCCLS method (89%) than with the AFST-EUCAST procedure (94%). Both the EUCAST and the E-test procedures can be reliable techniques for susceptibility testing of yeasts to voriconazole and caspofungin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354895      PMCID: PMC130859          DOI: 10.1128/JCM.40.10.3841-3844.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Authors:  Thomas J Walsh; Peter Pappas; Drew J Winston; Hillard M Lazarus; Finn Petersen; John Raffalli; Saul Yanovich; Patrick Stiff; Richard Greenberg; Gerald Donowitz; Mindy Schuster; Annette Reboli; John Wingard; Carola Arndt; John Reinhardt; Susan Hadley; Robert Finberg; Michél Laverdière; John Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

2.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

3.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method.

Authors:  E Chryssanthou
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

5.  Caspofungin.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.

Authors:  M Cuenca-Estrella; B Ruiz-Díez; J V Martínez-Suárez; A Monzón; J L Rodríguez-Tudela
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

8.  In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies.

Authors:  C Girmenia; C Tuccinardi; S Santilli; F Mondello; M Monaco; A Cassone; P Martino
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

9.  Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Houston; K Mills; A Bolmstrom; R N Jones
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

Review 10.  Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.

Authors:  A H Groll; T J Walsh
Journal:  Expert Opin Investig Drugs       Date:  2001-08       Impact factor: 6.206

View more
  35 in total

1.  Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

2.  Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.

Authors:  Vânia Lúcia Ribeiro da Matta; Márcia de Souza Carvalho Melhem; Arnaldo Lopes Colombo; Maria Luiza Moretti; Laura Rodero; Gisele Madeira Duboc de Almeida; Marilena dos Anjos Martins; Silvia Figueiredo Costa; Maria Beatriz G Souza Dias; Márcio Nucci; Anna S Levin
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

3.  Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006.

Authors:  E Dannaoui; O Lortholary; D Raoux; M E Bougnoux; G Galeazzi; C Lawrence; D Moissenet; I Poilane; D Hoinard; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

4.  Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance.

Authors:  Peter M Silver; Brian G Oliver; Theodore C White
Journal:  Med Mycol       Date:  2008-05       Impact factor: 4.076

5.  Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.

Authors:  M A Pfaller; A Espinel-Ingroff; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-01-12       Impact factor: 5.948

Review 6.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

7.  International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

8.  Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration.

Authors:  L Majoros; G Kardos; B Szabó; M Sipiczki
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

9.  In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.

Authors:  Ana Paula Miranda Duarte; Fernando Carlos Pagnocca; Noemi Carla Baron; Marcia de Souza Carvalho Melhem; Gislene Aparecida Palmeira; Dejanira de Franceschi de Angelis; Derlene Attili-Angelis
Journal:  Mycopathologia       Date:  2012-11-16       Impact factor: 2.574

10.  Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.

Authors:  Kevin C Hazen; Ellen Jo Baron; Arnaldo Lopes Colombo; Corrado Girmenia; Aurora Sanchez-Sousa; Amalia del Palacio; Catalina de Bedout; David L Gibbs
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.